NFASC
Neurofascin
Also known as: FLJ46866, KIAA0756, NF, NFASC_HUMAN, NRCAML
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O94856
- Gene
- NFASC
- Ensembl
- ENSG00000163531
- Chromosome
- 1
- Canonical length
- 1347 aa
- Protein class
- Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes an L1 family immunoglobulin cell adhesion molecule with multiple IGcam and fibronectin domains. The protein functions in neurite outgrowth, neurite fasciculation, and organization of the axon initial segment (AIS) and nodes of Ranvier on axons during early development. Both the AIS and nodes of Ranvier contain high densities of voltage-gated Na+ (Nav) channels which are clustered by interactions with cytoskeletal and scaffolding proteins including this protein, gliomedin, ankyrin 3 (ankyrin-G), and betaIV spectrin. This protein links the AIS extracellular matrix to the intracellular cytoskeleton. This gene undergoes extensive alternative splicing, and the full-length nature of some variants has not been determined.[provided by RefSeq, May 2009]
Canonical amino-acid sequenceUniProt
1347 residues, UniProt reviewed canonical sequence.
>O94856|NFASC
1 MARQPPPPWV HAAFLLCLLS LGGAIEIPMD PSIQNELTQP PTITKQSAKD HIVDPRDNIL
61 IECEAKGNPA PSFHWTRNSR FFNIAKDPRV SMRRRSGTLV IDFRSGGRPE EYEGEYQCFA
121 RNKFGTALSN RIRLQVSKSP LWPKENLDPV VVQEGAPLTL QCNPPPGLPS PVIFWMSSSM
181 EPITQDKRVS QGHNGDLYFS NVMLQDMQTD YSCNARFHFT HTIQQKNPFT LKVLTTRGVA
241 ERTPSFMYPQ GTASSQMVLR GMDLLLECIA SGVPTPDIAW YKKGGDLPSD KAKFENFNKA
301 LRITNVSEED SGEYFCLASN KMGSIRHTIS VRVKAAPYWL DEPKNLILAP GEDGRLVCRA
361 NGNPKPTVQW MVNGEPLQSA PPNPNREVAG DTIIFRDTQI SSRAVYQCNT SNEHGYLLAN
421 AFVSVLDVPP RMLSPRNQLI RVILYNRTRL DCPFFGSPIP TLRWFKNGQG SNLDGGNYHV
481 YENGSLEIKM IRKEDQGIYT CVATNILGKA ENQVRLEVKD PTRIYRMPED QVARRGTTVQ
541 LECRVKHDPS LKLTVSWLKD DEPLYIGNRM KKEDDSLTIF GVAERDQGSY TCVASTELDQ
601 DLAKAYLTVL ADQATPTNRL AALPKGRPDR PRDLELTDLA ERSVRLTWIP GDANNSPITD
661 YVVQFEEDQF QPGVWHDHSK YPGSVNSAVL RLSPYVNYQF RVIAINEVGS SHPSLPSERY
721 RTSGAPPESN PGDVKGEGTR KNNMEITWTP MNATSAFGPN LRYIVKWRRR ETREAWNNVT
781 VWGSRYVVGQ TPVYVPYEIR VQAENDFGKG PEPESVIGYS GEDYPRAAPT EVKVRVMNST
841 AISLQWNRVY SDTVQGQLRE YRAYYWRESS LLKNLWVSQK RQQASFPGDR LRGVVSRLFP
901 YSNYKLEMVV VNGRGDGPRS ETKEFTTPEG VPSAPRRFRV RQPNLETINL EWDHPEHPNG
961 IMIGYTLKYV AFNGTKVGKQ IVENFSPNQT KFTVQRTDPV SRYRFTLSAR TQVGSGEAVT
1021 EESPAPPNEA TPTAAPPTLP PTTVGATGAV SSTDATAIAA TTEATTVPII PTVAPTTIAT
1081 TTTVATTTTT TAAATTTTES PPTTTSGTKI HESAPDEQSI WNVTVLPNSK WANITWKHNF
1141 GPGTDFVVEY IDSNHTKKTV PVKAQAQPIQ LTDLYPGMTY TLRVYSRDNE GISSTVITFM
1201 TSTAYTNNQA DIATQGWFIG LMCAIALLVL ILLIVCFIKR SRGGKYPVRE KKDVPLGPED
1261 PKEEDGSFDY SDEDNKPLQG SQTSLDGTIK QQESDDSLVD YGEGGEGQFN EDGSFIGQYT
1321 VKKDKEETEG NESSEATSPV NAIYSLALocalizationUniProt · AlphaFold · HPA
Whether an antibody against NFASC can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.36
- Highest tissue expression
- 32 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 32 nTPM
- retina: 21 nTPM
- ovary: 16 nTPM
- seminal vesicle: 16 nTPM
- heart muscle: 14 nTPM
- smooth muscle: 13 nTPM
Single-cell type
- podocytes: 1,256 nCPM
- oligodendrocytes: 576 nCPM
- retinal horizontal cells: 419 nCPM
- rod photoreceptor cells: 321 nCPM
- corticotrophs: 231 nCPM
- retinal bipolar cells: 217 nCPM
Immune cell
- gdT-cell: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- white matter: 225 nTPM
- thalamus: 201 nTPM
- basal ganglia: 191 nTPM
- cerebral cortex: 178 nTPM
- midbrain: 155 nTPM
- medulla oblongata: 154 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about NFASC.
Disease | AllUniProt
Conditions NFASC is implicated in, by any mechanism.
- Neurodevelopmental disorder with central and peripheral motor dysfunction (NEDCPMD) MIM:618356
Disease | GeneticClinVar
13 pathogenic / likely-pathogenic of 346 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Neurodevelopmental disorder with central and peripheral motor dysfunction
- Inborn genetic diseases
Disease | AutoantibodyPubMed
Conditions in which antibodies against NFASC are reported. Each links to that disease's full target list.
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 43
- Peripheral Nervous System Diseases 12
- Guillain-Barre Syndrome 7
- Multiple Sclerosis 6
- Autoimmune Diseases of the Nervous System 5
- Encephalomyelitis, Autoimmune, Experimental 4
- Polyneuropathies 3
Showing 7 of 8 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for NFASC from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
92 publications
- Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg.
2014 · Neurology · RCR 11.2 · 294 citations - Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype.
2020 · Neurol Neuroimmunol Neuroinflamm · RCR 8.7 · 151 citations - Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies.
2017 · J Neurol Neurosurg Psychiatry · RCR 7.6 · 158 citations - Neurofascin as a novel target for autoantibody-mediated axonal injury.
2007 · J Exp Med · RCR 7.1 · 307 citations - Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage.
2023 · Brain · RCR 6.6 · 50 citations
Show 20 more of 92 total
- Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy.
2021 · Brain · RCR 6.5 · 79 citations - Neurofascin as a target for autoantibodies in peripheral neuropathies.
2012 · Neurology · RCR 6.4 · 196 citations - Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera.
2020 · J Neurol · RCR 6.1 · 94 citations - Daratumumab for treatment-refractory antibody-mediated diseases in neurology.
2022 · Eur J Neurol · RCR 6 · 65 citations - Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders.
2021 · Neurol Neuroimmunol Neuroinflamm · RCR 5.6 · 78 citations - Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies.
2018 · Neurology · RCR 4.8 · 90 citations - Anti-neurofascin antibody in patients with combined central and peripheral demyelination.
2013 · Neurology · RCR 4.6 · 135 citations - Growing Spectrum of Autoimmune Nodopathies.
2023 · Curr Neurol Neurosci Rep · RCR 4.5 · 32 citations - IgG1 pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality.
2021 · J Neurol Neurosurg Psychiatry · RCR 4.2 · 51 citations - Clinical profile of autoimmune nodopathy with anti-neurofascin 186 antibody.
2023 · Ann Clin Transl Neurol · RCR 4.1 · 29 citations - Autoimmune nodopathies, an emerging diagnostic category.
2022 · Curr Opin Neurol · RCR 4.1 · 39 citations - Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies.
2022 · Neurotherapeutics · RCR 4.1 · 39 citations - Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort.
2023 · J Neurol Neurosurg Psychiatry · RCR 3.8 · 26 citations - Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-Neurofascin 155 antibodies.
2017 · Neuromuscul Disord · RCR 3.6 · 79 citations - Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism.
2021 · Front Neurol · RCR 3.3 · 42 citations - Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins.
2020 · Clin Neurophysiol · RCR 3 · 43 citations - Clinical Features of Autoimmune Nodopathy With Anti-Neurofascin-155 Antibodies in South Koreans.
2024 · J Clin Neurol · RCR 2.9 · 11 citations - Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis.
2009 · Brain · RCR 2.9 · 102 citations - Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy.
2017 · Sci Rep · RCR 2.8 · 68 citations - Anti-neurofascin autoantibody and demyelination.
2019 · Neurochem Int · RCR 2 · 45 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.22
- gnomAD pLI
- 1
- gnomAD missense Z
- 2.59
- DepMap mean gene effect
- 0.05
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Immunoglobulin subtype 2
- Immunoglobulin domain subtype
- Fibronectin type III
- Immunoglobulin-like domain
- Immunoglobulin I-set
- Immunoglobulin-like beta-sandwich domain
- Immunoglobulin-like fold
- Neurofascin/L1/NrCAM, C-terminal domain
- Fibronectin type III superfamily
- Immunoglobulin-like domain superfamily
- Fibronectin type III domain
- Immunoglobulin domain
- Immunoglobulin I-set domain
- Bravo-like intracellular region
- Immunoglobulin domain
- Neurofascin, immunoglobulin-like domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of NFASC in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NFASC as an antibody target. Whether an autoantibody or antibody against NFASC could matter depends on whether native NFASC is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NFASC is annotated at the cell surface, where native NFASC is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label NFASC as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...